Our Strengths

Avisa Pharma Advanced Research Centre, founded in March 2023, is a research-driven pharmaceutical company in the pharmaceutical domain. Established by Mr. Rajesh Pawar, a seasoned technocrat with approximately three decades of industry expertise, the company boasts a dedicated R&D team comprising highly skilled professionals.

At Avisa Pharma Advanced Research Centre, our specialized focus lies in the research and development of Cephalosporins, Carbapenems and Cardiovascular APIs and synthetic API molecules. We are dedicated to developing complex API molecules tailored for critical care applications such as Cardiovascular treatment, Macrolides, Anti-inflammatory drug, Antihypertensive, Cephalosporins, Carbapenems and various antibacterial conditions.

Under the adept leadership of seasoned technocrats with a commendable industrial track record, our R&D team comprises skilled professionals. Avisa Pharma has achieved significant milestones in research and development, successfully scaling several molecules, underscoring our confidence in our proprietary technology. 

Currently, we are poised to broaden our product portfolio to meet both domestic and international demands through the imminent expansion of our manufacturing infrastructure. Our paramount objective is to foster a healthier world through accessible disease management solutions.

Avisa Pharma Advanced Research Centre is a dedicated, goal-oriented organization striving to become a pivotal player in the pharmaceutical arena. Our vision centres on establishing a distinctive niche in global complex API molecules. We remain steadfast in fulfilling our commitments to clients, stakeholders, and employees alike.

Our state-of-the-art infrastructure underscores our commitment to product quality, safety, and efficacy, serving as the cornerstone of our client-centric approach. We offer our product range at competitive prices across regulated markets globally.

Spanning 6000 sq. ft., Avisa Pharma Advanced Research Centre R&D facility encompasses chemical synthesis, and analytical laboratories. Additionally, we have established a commercial manufacturing unit within our existing facility dedicated to producing Cephalosporins, Carbapenems and Cardiovascular APIs and synthetic API molecules.